China pharmaceutical engineering conference was successfully held——Lefancaps actively participated as a lecturer
From 4th to 6th November, 2017 China pharmaceutical engineering conference hosted by CFDA of international exchange center, SFDA of food and drug audit inspection center, ISPE, was held successfully in Shanghai. Pharmaceutical supervision department, well-known expert in biopharmaceutical field from domestic and foreign, well-known enterprise representative attended this grand conference.
This conference focused on biological drug related policies and regulations, automatic production and MES, drug administration new technology, CMC life cycle, clinical trial drugs administration, biopharmaceutical trials, process verification and facility design, quality risk management, drug GMP, drug GSP and so on. CFDA deputy director Jinglin SUN, FDA national assistant director Lane Christensen, German SFDA Gabriele, AstraZeneca global quality vice president Athony Mire-Sluis and other experts made a report respectively. They made wonderful replies and full discussion about concerns of the people present.
Process verification and factory design implementation(CIFA share) as one of the contents of this conference was held on 5th November. Quality department manager——Zhiwen ZHENG from Lefancaps shared the study on consistency evaluation of pharmaceutical excipient in quality and therapeutic effect of generic drugs with the people present. Mr. ZHENG demonstrated and explained deeply in drug regulation compliance,drug dissolution rate,drug stability and drug impurities. He made full interaction withthe peoplepresence.The atmosphere is warm and academic atmosphere is strong.
This conference provided new vision, new concepts and new thoughts for industrialization research of biopharmaceutical. Thepeoplepresent benefits a lot. Successful holding of this conference had great significance to enhance biopharmaceutical research and academic exchange from domestic and foreign production peopleand improve the industrialization level of bio-pharmaceutical industry in China.